Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.5
3.9
Journals
Toxins
Special Issues
Botulinum Toxin in Neuro-Rehabilitation: Expanding Horizons in Spasticity and Beyond
share announcement

Botulinum Toxin in Neuro-Rehabilitation: Expanding Horizons in Spasticity and Beyond

A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".

Deadline for manuscript submissions: 30 March 2025 | Viewed by 1022

Special Issue Editors

Dr. Stefano Tamburin

E-Mail Website
Guest Editor
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37100 Verona, Italy
Interests: pain; neurodegenerative disorders; movement disorders; neurorehabilitation
Special Issues, Collections and Topics in MDPI journals
Dr. Alessandro Picelli

E-Mail Website
Guest Editor
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37100 Verona, Italy
Interests: botulinum toxins; muscle spasticity; movement disorders; rehabilitation; ultrasound
Special Issues, Collections and Topics in MDPI journals
Dr. Mirko Filippetti

E-Mail Website
Guest Editor
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37100 Verona, Italy
Interests: botulinum toxins; muscle spasticity; pain; movement disorders; rehabilitation; ultrasound

Special Issue Information

Dear Colleagues,

This Special Issue, titled “Botulinum Toxin in Neuro-Rehabilitation: Expanding Horizons in Spasticity and Beyond”, will explore the evolving role of botulinum neurotoxin in neuro-rehabilitation practices. Current research highlights botulinum neurotoxin’s therapeutic potential beyond its traditional applications in managing spasticity, focusing on its effects on pain management, quality of life and other relevant outcomes in various neurological conditions characterized by spasticity. However, significant challenges remain, including optimizing dose, achieving better goals, developing strategies to pinpoint spasticity earlier and treating it sooner.

This Special Issue is devoted to all the above themes, with a particular focus on the fields of neurology, neurorehabilitation and pain medicine. Randomized controlled trials, original reports, innovative and informative case studies or series, systematic reviews and meta-analyses in human populations, as well as experimental studies in animal models, are all welcome.

Dr. Stefano Tamburin
Dr. Alessandro Picelli
Dr. Mirko Filippetti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • botulinum neurotoxin
  • neurology
  • neurorehabilitation
  • Parkinson’s disease
  • rehabilitation
  • dystonia
  • movement disorders
  • pain
  • stroke
  • spasticity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

6 pages, 241 KiB  
Opinion
Does the Diffusion Profile Differ Between Botulinum Toxin Type a Formulations? Implications for the Management of Post-Stroke Spasticity
by Alessandro Picelli, Stefano Tamburin, Rita Di Censo, Nicola Smania and Mirko Filippetti
Toxins 2024, 16(11), 480; https://doi.org/10.3390/toxins16110480 - 7 Nov 2024
Viewed by 836
Abstract
Botulinum toxin type A is a first-line treatment for post-stroke spasticity, with selective action at nerve endings and minimal effects beyond the injection site. However, concerns about potential adverse reactions due to toxin diffusion and spread can significantly influence physicians’ therapeutic decisions in [...] Read more.
Botulinum toxin type A is a first-line treatment for post-stroke spasticity, with selective action at nerve endings and minimal effects beyond the injection site. However, concerns about potential adverse reactions due to toxin diffusion and spread can significantly influence physicians’ therapeutic decisions in managing post-stroke spasticity. Current evidence shows that while the main formulations of botulinum toxin type A have different molecular weights and sizes, they do not exhibit differing diffusion profiles. Instead, the key factors determining botulinum toxin type A diffusion and spread in post-stroke spasticity management are the dose (i.e., the actual amount of 150 kDa neurotoxin protein injected), dilution, and injection volume. Other injection-related factors, such as the needle gauge and injection speed, have also been suggested to have a secondary influence on botulinum toxin type A diffusion and spread. The needs of patients with post-stroke spasticity may vary, and depending on treatment goals, botulinum toxin type A diffusion and spread can be something to avoid or may offer therapeutic benefits by reaching a greater number of nerve terminals in the target muscle, enhancing the toxin’s effect. These factors should be carefully evaluated in spasticity clinics. Full article
(This article belongs to the Special Issue Botulinum Toxin in Neuro-Rehabilitation: Expanding Horizons in Spasticity and Beyond)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop